CE Holdings (4320) Q2 2025 earnings summary

Executive summary

• Achieved record-high sales and profits for the second quarter, driven by strong electronic medical record (EMR) system sales and increased user base, with maintenance services also performing well.

• Net sales rose 14.0% year-over-year to ¥9,199 million for the six months ended March 31, 2025, with operating profit up 66.0% to ¥1,230 million and profit attributable to owners of parent up 90.4% to ¥707 million.

• Earnings per share increased to ¥46.48 from ¥24.77 year-over-year.

• Operating, ordinary, and net income all saw significant year-over-year growth, supported by both revenue increase and reduced SG&A expenses in pharmaceutical and medical device development support.

Financial highlights

• Revenue for Q2 rose 14.0% year-over-year to ¥9,199 million.

• Operating income increased 66.0% to ¥1,230 million; ordinary income up 66.6% to ¥1,239 million.

• Net income attributable to parent rose 90.4% to ¥707 million.

• Gross profit increased to ¥2,284 million from ¥1,879 million year-over-year, while selling, general and administrative expenses decreased.

• Total assets grew to ¥12,679 million as of March 31, 2025, up from ¥11,251 million at the previous fiscal year-end.

Outlook and guidance

• Full-year guidance maintained, with record-high revenue, operating income, and net income expected.

• Full-year net sales forecasted at ¥15,000 million, up 3.1% year-over-year.

• Operating and ordinary profit both projected at ¥1,500 million, up 30.6% year-over-year.

• Profit attributable to owners of parent expected to reach ¥820 million, with EPS forecasted at ¥54.23.

• Dividend per share forecasted at ¥22.00 for the fiscal year ending September 30, 2025.